Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients
Key facts
- Who runs it
- University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 74 people enrolled
- Started
- 11 Sept 2023
- Ended
- 16 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fluzone High-Dose - 2 doses
- Fluzone High-Dose - 1 dose of HD
- Record updated
- 15 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- >=18 years old who underwent a solid organ transplant (Liver, lung, heart, kidney, pancreas) > 1 year prior to enrollment
- At least 1-year post-transplant
- Able and willing to provide informed consent
- Able and willing to undergo all study activities throughout the duration of the study
Who cannot take part
- History of a severe allergy to influenza vaccine (i.e. Guillain Barre syndrome, anaphylaxis or angioedema)
- Confirmed pregnancy
- Receipt of ATG or carfilzomib within the past 3 months
- Receipt of rituximab within the past 3 months
- Receipt of basiliximab within the past 3 months
- Prednisone dose >= 20 mg/day at the time of enrollment
Where in United States
- University of MinnesotaMinneapolis, United States
About the trial
What the trial wants to find out
In solid organ transplant (SOT) the receipt of influenza vaccine in an influenza season is associated with decreased disease severity as demonstrated by the presence of pneumonia and ICU admissions. Different strategies have been assessed to optimize vaccine efficacy and immunogenicity of the influenza vaccine in the solid organ transplant recipient (SOTR). The primary objective of the study is to evaluate the immunogenicity of 2 doses of the high dose influenza vaccine utilizing neutralizing antibody assays. A control group receiving 1 HD influenza vaccine will be included.
The 2 groups in the trial
- booster groupTreatment being tested
Participants who have undergone a solid organ transplant will receive two doses of an inactivated high dose influenza vaccine
Treatment: Fluzone High-Dose - 2 doses
- Control groupExisting treatment, for comparison
Participants who have undergone a solid organ transplant will receive one dose of inactivated high dose influenza vaccine followed by a placebo injection
Treatment: Fluzone High-Dose - 1 dose of HD
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- A Randomized, Double-Blind Clinical Trial of One vs Two Doses of High-Dose Influenza Vaccine in Solid Organ Transplant Recipients.Open forum infectious diseases, 2026
- Record updated
- 15 July 2025